Amarin

Jefferies initiated coverage of Cisco Systems (NASDAQ: CSCO) with a Hold rating. At the same time, Jefferies put its price target on the company's stock to $15.75. In a research report published today, Jefferies states, "We believe it's too early for investors to commit to the stock as we're still...

Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "A competitor has raised questions raised over the validity of the statistical analyses used in the MARINE and ANCHOR studies, but for reasons we outline below, we remain...

Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "We had an opportunity to spend time with AMRN senior management to discuss potential scenarios for a pharma partnership or acquisition, AMR101 regulatory filings, and the CV...

Jefferies is out with its report today on Amarin (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "The National Heart, Lung, and Blood Institute announced discontinuation of the AIM-HIGH trial, concluding that niacin with statin would not show benefit over statin alone in...

Jefferies is out with its report today on Amarin Corp. (NASDAQ: AMRN), maintaining Buy. In a note to clients, Jefferies writes, "We believe AMR101 offers robust efficacy for hyperlipidemia, lowering triglycerides without raising cholesterol like Lovaza. With a cleaner profile and potentially a...